| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Chief Scientific Officer
1 company
George Adi Mor is Chief Executive Officer at CMMB. George Adi Mor's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $24K at current prices.
Our model assigns George Adi Mor a strong insider score of 78/100, based on 3 past trades. Over a 12-month horizon, both of those trades were profitable, with an average 12-month return of +76.4%.
The CMMB filings lean toward selling, a net 586,019 shares.
George Adi Mor has 3 Form 4 filings on record from November 2022 to May 2026, all as Chief Executive Officer at Chemomab Therapeutics (CMMB), 2022–2026.
The 12 reported transactions were 4 open-market sales, 4 option or other derivative awards, 2 open-market purchases and 2 other transactions.
Counted by filing, the open-market trades come to 1 purchase worth about $20K and 2 sales worth about $1.3M.
The only open-market purchase was 9,804 shares of CMMB at an average $2.07 on May 29, 2026, about $20K.
The largest open-market sale was 582,023 shares of CMMB at an average $2.08 on November 16, 2022, about $1.2M. Twelve months later CMMB was down 71%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | CMMB Chemomab Therapeutics Ltd. | Chief Executive Officer | Buy | 9,804 | $2.07 | $20,245.98 | +7.6% | +36.0% | - | |
| Jan 3, 2023 | CMMB Chemomab Therapeutics Ltd. | Chief Scientific Officer | Sell | 13,800 | $5.03 | $69,369.84 | -5.2% | -49.0% | -81.8% | |
| Nov 16, 2022 | CMMB Chemomab Therapeutics Ltd. | Chief Scientific Officer | Sell | 582,023 | $2.08 | $1,213,401.55 | -69.3% | -9.2% | -71.1% |